STOCK TITAN

Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Alnylam Pharmaceuticals (NASDAQ: ALNY) will report its third-quarter financial results on October 27, 2022, before U.S. market opening. The management will hold a conference call on the same date at 8:30 am ET to discuss the results and future expectations. A live audio webcast will be available on the company's investor website. Alnylam continues to lead in RNA interference therapeutics, offering products like ONPATTRO and GIVLAARI, and has a robust pipeline with six late-stage candidates. The firm is committed to developing innovative medicines for rare diseases.

Positive
  • Strong pipeline with six late-stage product candidates.
  • Continued leadership in RNA interference therapeutics.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.

Management will provide an update on the Company and discuss third quarter 2022 results as well as expectations for the future via conference call on Thursday, October 27, 2022 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI1581caadac4f4c80820e2eb8a001b2c3. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals report third-quarter earnings?

Alnylam Pharmaceuticals will report its third-quarter earnings on October 27, 2022.

What time is the conference call for Alnylam's Q3 results?

The conference call for Alnylam's Q3 results is scheduled for October 27, 2022, at 8:30 am ET.

How can I access the webcast for Alnylam's earnings call?

You can access the live audio webcast for Alnylam's earnings call on their investor website.

What products does Alnylam Pharmaceuticals currently offer?

Alnylam Pharmaceuticals offers RNAi therapeutic products such as ONPATTRO and GIVLAARI.

How is Alnylam's pipeline currently structured?

Alnylam has a pipeline that includes six product candidates in late-stage development.

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

ALNY Rankings

ALNY Latest News

ALNY Stock Data

30.67B
128.18M
0.43%
98.2%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE